RU2377254C2 - Мутанты анти-cd40 антитела - Google Patents

Мутанты анти-cd40 антитела Download PDF

Info

Publication number
RU2377254C2
RU2377254C2 RU2006126979A RU2006126979A RU2377254C2 RU 2377254 C2 RU2377254 C2 RU 2377254C2 RU 2006126979 A RU2006126979 A RU 2006126979A RU 2006126979 A RU2006126979 A RU 2006126979A RU 2377254 C2 RU2377254 C2 RU 2377254C2
Authority
RU
Russia
Prior art keywords
monoclonal antibody
seq
represented
human
amino acid
Prior art date
Application number
RU2006126979A
Other languages
English (en)
Other versions
RU2006126979A (ru
Inventor
Нобуаки ТАКАХАСИ (JP)
Нобуаки Такахаси
Тору МИУРА (JP)
Тору Миура
Йосинори КИТАГАВА (JP)
Йосинори Китагава
Аки ХИРАНО (JP)
Аки Хирано
Original Assignee
Кирин Фарма Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кирин Фарма Кабусики Кайся filed Critical Кирин Фарма Кабусики Кайся
Publication of RU2006126979A publication Critical patent/RU2006126979A/ru
Application granted granted Critical
Publication of RU2377254C2 publication Critical patent/RU2377254C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Настоящее изобретение относится к иммунологии и биотехнологии. Предложены варианты моноклонального антитела-антагониста к CD40, вариабельные области которых происходят из антитела, полученного из гибридомы 4D11 (FERM ВР-7758). Константные области антител происходят из IgG4 человека и имеют мутации S228P и L235E. Описаны соответствующие кодирующие полинуклеотиды и вектор экспрессии на их основе. Раскрыта клетка-хозяин, содержащая вектор. Описан способ получения моноклонального антитела и его использование в составе фармацевтической композиции. Использование изобретения обеспечивает сниженные активности ADCC и CDC, что может найти применение в терапии аутоиммунных заболеваний и отторжения трансплантанта. 10 н.п. ф-лы, 26 ил., 2 табл.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
Figure 00000166
Figure 00000167
Figure 00000168
Figure 00000169
Figure 00000170
Figure 00000171
Figure 00000172
Figure 00000173
Figure 00000174
Figure 00000175
Figure 00000176
Figure 00000177

Claims (10)

1. Моноклональное антитело, связывающееся с CD40 человека, состоящее из (i) двух тяжелых цепей, каждая из которых содержит константную область, полученную из IgG4 человека, с замещением серина пролином в положении 228 и замещением лейцина глутаминовой кислотой в положении 235, и вариабельную область из тяжелой цепи моноклонального антитела, продуцируемого гибридомой 4D11 (№ доступа FERM ВР-7758), и (ii) двух легких цепей, каждая из которых содержит вариабельную область из легкой цепи моноклонального антитела, продуцируемого гибридомой 4D11 (№ доступа FERM ВР-7758).
2. Моноклональное антитело, связывающееся с CD40 человека, состоящее из (i) двух тяжелых цепей, каждая из которых содержит константную область, полученную из IgG4 человека, с замещением серина пролином в положении 228 и замещением лейцина глутаминовой кислотой в положении 235, и вариабельную область, представленную аминокислотной последовательностью в диапазоне от Q в положении 27 до S в положении 147 в SEQ ID NO:46, и (ii) двух легких цепей, каждая из которых содержит вариабельную область, представленную аминокислотной последовательностью в диапазоне от А в положении 23 до К в положении 128 в SEQ ID NO:48.
3. Моноклональное антитело, связывающееся с CD40 человека, состоящее из двух тяжелых цепей, каждая из которых представлена аминокислотной последовательностью в диапазоне от Q в положении 27 до К в положении 474 в SEQ ID NO:140, и двух легких цепей, каждая из которых представлена аминокислотной последовательностью в диапазоне от А в положении 23 до С в положении 235 в SEQ ID NO:142.
4. Полинуклеотид, представленный SEQ ID NO:139, для получения антитела по любому из пп.1-3.
5. Полинуклеотид, представленный последовательностью в диапазоне от С в положении 79 до А в положении 1425 в SEQ ID NO:139, для получения антитела по любому из пп.1-3.
6. Вектор экспрессии, содержащий полинуклеотид, представленный SEQ ID NO:139, и полинуклеотид, представленный SEQ ID NO:141, для получения антитела по любому из пп.1-3.
7. Клетка-хозяин, содержащий вектор экспрессии по п.6.
8. Способ получения моноклонального антитела, предусматривающий стадии культивирования клетки-хозяина по п.7 в культуральной среде и получения моноклонального антитела из культуры и/или хозяина.
9. Фармацевтическая композиция, содержащая эффективную дозу моноклонального антитела по любому из пп.1-3 в качестве активного ингредиента для профилактики или лечения отторжения трансплантата, аутоиммунных заболеваний, аллергии или ингибирования фактора VIII свертывания крови.
10. Применение моноклонального антитела по любому из пп.1-3 для получения фармацевтической композиции для профилактики или лечения отторжения трансплантата, аутоиммунных заболеваний, аллергии или ингибирования фактора VIII свертывания крови.
RU2006126979A 2003-12-25 2004-12-24 Мутанты анти-cd40 антитела RU2377254C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003431408 2003-12-25
JP2003-431408 2003-12-25

Publications (2)

Publication Number Publication Date
RU2006126979A RU2006126979A (ru) 2008-01-27
RU2377254C2 true RU2377254C2 (ru) 2009-12-27

Family

ID=34736433

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006126979A RU2377254C2 (ru) 2003-12-25 2004-12-24 Мутанты анти-cd40 антитела

Country Status (25)

Country Link
US (4) US8568725B2 (ru)
EP (1) EP1707627B1 (ru)
JP (2) JP4242388B2 (ru)
KR (2) KR101223373B1 (ru)
CN (1) CN1922316B (ru)
AU (1) AU2004309275B2 (ru)
BR (1) BRPI0417266B8 (ru)
CA (1) CA2551008C (ru)
CY (1) CY1114019T1 (ru)
DK (1) DK1707627T3 (ru)
EC (1) ECSP066710A (ru)
ES (1) ES2397631T3 (ru)
HK (1) HK1102134A1 (ru)
HR (1) HRP20130078T1 (ru)
IL (1) IL176508A (ru)
NO (1) NO344608B1 (ru)
NZ (1) NZ548325A (ru)
PL (1) PL1707627T3 (ru)
PT (1) PT1707627E (ru)
RU (1) RU2377254C2 (ru)
SI (1) SI1707627T1 (ru)
TW (1) TW200540186A (ru)
UA (1) UA93027C2 (ru)
WO (1) WO2005063981A1 (ru)
ZA (1) ZA200605874B (ru)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2551008C (en) 2003-12-25 2013-10-01 Kirin Beer Kabushiki Kaisha Anti-cd40 antibody mutants
US8716451B2 (en) 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2008133983A1 (en) 2007-04-25 2008-11-06 Immurx, Inc. Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
TWI464262B (zh) 2007-09-26 2014-12-11 中外製藥股份有限公司 抗體固定區的變異
WO2009041734A1 (ja) * 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. ヒトトロンボポエチン受容体に対するアゴニスト抗体
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
BRPI0821447A2 (pt) * 2007-12-26 2015-06-16 Biotest Ag Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
DK2242772T3 (en) 2007-12-26 2015-01-05 Biotest Ag Immunoconjugates that targets CD138, and uses thereof
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
HUE028958T2 (en) * 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
AR074438A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
WO2010064090A1 (en) * 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
BRPI1009455A2 (pt) * 2009-03-10 2016-03-01 Baylor Res Inst anticorpos anti-c40 e usos dos mesmos
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
CA2759146C (en) 2009-04-20 2017-06-13 Kyowa Hakko Kirin Co., Ltd. Agonist anti-cd40 antibody
JP2011041475A (ja) * 2009-08-19 2011-03-03 Asahi Kasei Medical Co Ltd 抗体製造方法
JP5837821B2 (ja) * 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
RS60612B1 (sr) 2010-03-31 2020-08-31 Boehringer Ingelheim Int Anti-cd40 antitela
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2734076T3 (es) * 2011-02-17 2019-12-04 Kyowa Hakko Kirin Co Ltd Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada
CN106279401A (zh) 2011-03-11 2017-01-04 贝丝以色列女执事医疗中心 Cd40片段及其用途
HUE038848T2 (hu) * 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
BR112013031892A2 (pt) * 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
PL2812443T3 (pl) * 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
JP6693745B2 (ja) 2012-10-30 2020-05-13 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
DK3030575T3 (en) 2013-08-08 2018-10-22 Cytune Pharma IL-15 AND IL-15R-ALFA-SUSHI DOMAIN-BASED MODULOKINES
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
CA2936833A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
JP6682498B2 (ja) * 2014-03-24 2020-04-15 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用
WO2016011401A1 (en) * 2014-07-18 2016-01-21 Kedl Ross M Immunostimulatory combinations and use thereof
CN113699116A (zh) 2014-12-10 2021-11-26 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
AR104809A1 (es) * 2015-05-29 2017-08-16 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
EA037882B1 (ru) * 2015-09-30 2021-05-31 Янссен Байотек, Инк. Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
TW201806972A (zh) 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 雙特異性結合蛋白
US10519243B2 (en) 2016-05-27 2019-12-31 Abbvie Biotherapeutics Inc. Anti-CD40 antibodies
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
US11471515B2 (en) 2016-11-09 2022-10-18 The Brigham And Women's Hospital, Inc. Restoration of tumor suppression using MRNA-based delivery system
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018187702A2 (en) 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20200074993A (ko) 2017-11-03 2020-06-25 노파르티스 아게 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
CN109971725B (zh) * 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
WO2019157087A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
CN111971307A (zh) 2018-04-13 2020-11-20 诺华股份有限公司 用于预防移植物排斥的抗cd40抗体
US11976123B2 (en) 2018-04-20 2024-05-07 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
CN116063495A (zh) * 2018-09-28 2023-05-05 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2019389354A1 (en) * 2018-11-30 2021-07-15 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof
EP3908310A1 (en) 2019-01-11 2021-11-17 Novartis AG Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
KR20220007086A (ko) 2019-05-08 2022-01-18 노파르티스 아게 T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
AU2019465294A1 (en) 2019-09-11 2022-03-24 Novartis Ag A method for preventing human virus associated disorders in patients
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
DE3737506A1 (de) 1987-11-05 1989-05-24 Ibm Deutschland Vorrichtung zur bestueckung insbesondere von leiterplatten
JPH0725784B2 (ja) 1989-09-14 1995-03-22 鐘紡株式会社 アルコール刺激臭暖和剤
NZ282849A (en) * 1994-03-29 1998-05-27 Celltech Therapeutics Ltd Antibodies against e-selectin; whole antibodies of neutral isotype, being variants of natural antibodies altered in the fc region
CA2327505A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6998124B1 (en) * 1999-04-14 2006-02-14 Smithkline Beecham Corporation Erythropoietin receptor antibodies
JP2002544123A (ja) * 1999-04-14 2002-12-24 スミスクライン・ビーチャム・コーポレイション エリトロポイエチン受容体抗体
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
EP2011802A3 (en) * 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
EP1369431A4 (en) * 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2551008C (en) 2003-12-25 2013-10-01 Kirin Beer Kabushiki Kaisha Anti-cd40 antibody mutants
ES2734076T3 (es) * 2011-02-17 2019-12-04 Kyowa Hakko Kirin Co Ltd Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Idusogie ЕЕ et al. "Mapping of the Clq binding site on rituxan, a chimeric antibody with a human IgGI Fc", J Immunol. 2000 Apr 15; 164(8), стр.4178-84. Reddy et al. "Elimination of Fc Receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4", The Journal of Immunology, 2000, 164, стр.1925-1933. *

Also Published As

Publication number Publication date
IL176508A (en) 2011-09-27
SI1707627T1 (sl) 2013-02-28
IL176508A0 (en) 2006-10-05
ES2397631T3 (es) 2013-03-08
UA93027C2 (ru) 2011-01-10
US20140248266A1 (en) 2014-09-04
TW200540186A (en) 2005-12-16
US20070148163A1 (en) 2007-06-28
ECSP066710A (es) 2006-11-24
BRPI0417266B8 (pt) 2021-05-25
JP2009022289A (ja) 2009-02-05
US20140105907A1 (en) 2014-04-17
PT1707627E (pt) 2013-01-24
US20150057437A1 (en) 2015-02-26
KR20120116018A (ko) 2012-10-19
WO2005063981A1 (ja) 2005-07-14
US8568725B2 (en) 2013-10-29
HK1102134A1 (en) 2007-11-09
CN1922316B (zh) 2011-03-23
NO20063197L (no) 2006-09-21
CA2551008C (en) 2013-10-01
JP4242388B2 (ja) 2009-03-25
CA2551008A1 (en) 2005-07-14
KR101223373B1 (ko) 2013-01-16
AU2004309275A1 (en) 2005-07-14
HRP20130078T1 (hr) 2013-02-28
KR20060130615A (ko) 2006-12-19
US9023360B2 (en) 2015-05-05
CN1922316A (zh) 2007-02-28
US9598494B2 (en) 2017-03-21
JPWO2005063981A1 (ja) 2007-07-19
EP1707627B1 (en) 2012-11-14
CY1114019T1 (el) 2016-07-27
AU2004309275B2 (en) 2010-12-23
PL1707627T3 (pl) 2013-04-30
KR101200188B1 (ko) 2012-11-13
NZ548325A (en) 2009-07-31
RU2006126979A (ru) 2008-01-27
BRPI0417266B1 (pt) 2020-04-28
TWI343389B (ru) 2011-06-11
EP1707627A4 (en) 2008-08-27
EP1707627A1 (en) 2006-10-04
BRPI0417266A (pt) 2007-03-13
ZA200605874B (en) 2008-04-25
DK1707627T3 (da) 2012-12-17
NO344608B1 (no) 2020-02-10
US9023361B2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
RU2377254C2 (ru) Мутанты анти-cd40 антитела
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
RU2395523C2 (ru) Антитела к ох40l
CN103649118A (zh) 双特异性结合剂
RU2012129735A (ru) Антитела к her3 и их применения
RU2011110169A (ru) Антитела против ccr2
RU2019105702A (ru) Антитело против lag-3
US20140199728A1 (en) Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
CN106519034A (zh) 抗pd‑1抗体及其用途
RU2011150916A (ru) Антитела против vegf и их применения
CN101001645A (zh) Il－17拮抗抗体
RU2012142230A (ru) Антитела против csf-1r человека и их применение
CN101512008A (zh) 白介素-13结合蛋白
WO2005059106A3 (en) Interferon alpha antibodies and their uses
NO336802B1 (no) Humane anti-IFN-gamma nøytraliserende antistoffer samt fremstilling derav, isolert polynukleotid, vektor, vertcelle og farmasøytisk sammensetning
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
HRP20240102T1 (hr) Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena
US10954292B2 (en) Anti-PACAP antibody
US11299760B2 (en) Use of monensin to regulate glycosylation of recombinant proteins
JP2014506259A (ja) Ｉｌ−２１リガンド
RU2019129569A (ru) ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
RU2003121231A (ru) Молчащие анти-cd28-антитела и их применение
CN101054416A (zh) HAb18GC2单抗和其轻、重链可变区基因、编码多肽及应用
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
CN109517064A (zh) 白介素-6的人源化单克隆抗体、其编码基因及应用

Legal Events

Date Code Title Description
HK4A Changes in a published invention